Brief: Pyxis Oncology Reports Quarterly Loss Of 85 Cents Per Share

Pyxis Oncology

01/11/2022 10:59

Nov 1 (Reuters) - Pyxis Oncology Inc  PYXS.O :
    * PYXIS ONCOLOGY REPORTS FINANCIAL RESULTS FOR THE QUARTER
ENDED
SEPTEMBER 30, 2022 AND PROVIDES CORPORATE UPDATE
    * QUARTERLY LOSS PER SHARE $0.85
    * EXPANDS WORLDWIDE LICENSING AGREEMENT WITH PFIZER TO
OBTAIN
ADDITIONAL ANTIBODY-DRUG CONJUGATE (ADC) PLATFORM COMPONENTS
    * GAINS EXCLUSIVE RIGHTS TO PFIZER’S ADC TECHNOLOGY PLATFORM
AND
TOOLKIT TO CERTAIN LICENSED TARGETS
    * REMAINS ON TRACK WITH IND PLANS FOR PYX-106 AND PYX-201 BY
END
OF THIS YEAR
    * PYXIS ONCOLOGY - CASH & CASH EQUIVALENTS (INCLUDING
RESTRICTED
CASH) OF $200.0 MILLION AS OF SEPT 30, 2022, EXPECTED TO FUND
OPERATIONS INTO END OF 2024
    * QTRLY LOSS PER SHARE $0.85
    * Q3 EARNINGS PER SHARE VIEW $-0.81 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXPndKz 
Further company coverage:  PYXS.O 
 ((Reuters.Briefs@thomsonreuters.com;))